Zacks Small Cap Research on MSN5 小时
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine…
XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Licensing Agreement with Norgine Includes €28.5 Million  Upfront Payment On3, 2025, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced an ...
Chromatin Bioscience's Synthetic Promoter Supports Esobiotec's ESO-T01 CAR-T Therapy As It ...
EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical ...
Too Old to Operate9 小时
Impact of Monocytic ROS on T Cell Response to SARS-CoV-2 mRNA Vaccine
The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...
Neurology Advisor7 小时
Ulcerative Hunner Lesions Can Help Characterize Bladder Pain, Infection
Distinct phenotypic and urine biological characteristics are seen for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with a history of ulcerative Hunner lesions (UIC) and those ...
生物谷19 小时
Nature Medicine：巨噬细胞疗法——肝硬化治疗的全新突破
巨噬细胞疗法为何被选为肝硬化治疗的新方向？答案在于其在纤维化逆转和组织修复中的独特作用。研究表明，巨噬细胞不仅能够吞噬和清除纤维组织，还能释放抗炎信号分子，调节免疫环境，进一步促进肝细胞再生。此外，早期动物实验的成功为其在人体应用奠定了理论基础，显示 ...